Eco Science Solutions: Zero revenue, $17.2M liabilities, going-concern risk

Eco Science Solutions, Inc. (PINK: ESSI) - Quick internal and income-statement snapshot

What's happening inside: management continues product development (Herbo / HerboPay) but the company has no operating revenue. Growth is funded by related-party loans and convertible notes while the former subsidiary Ga‑Du was dissolved (liabilities of $975,000 recorded as "liabilities held on divestiture"). Management warns of substantial doubt about the company's ability to continue as a going concern.

Key facts & statistics

- Revenue: $0 for the three months and six months ended July 31, 2025 (and $0 in comparable 2024 periods).

- Three months ended July 31, 2025 - Total operating expenses: $242,898; Net loss: $(262,843); Interest expense (total): $(19,945).

- Six months ended July 31, 2025 - Total operating expenses: $497,193; Net loss: $(536,264); Total other expense: $(39,071).

- Net loss per share (basic & diluted): $(0.01) for the six months ended July 31, 2025. Weighted average shares: 52,957,572.

- Balance sheet snapshot (July 31, 2025): Cash $3,098; Total assets $104,583; Total liabilities $17,203,119; Stockholders' deficit $(17,098,536); Accumulated deficit $79,262,536.

- Working capital: current assets $4,583 vs. current liabilities $17,203,119 - implied working capital deficit ~$(17.20 million) (company cites $17,198,536).

- Debt and related obligations: Convertible notes, net $1,656,213 (principal $1,407,781 + stock-settled debt liability $248,432); Notes payable total $2,960,118; Related-party payables $2,868,761; Notes payable, short-term, related party $4,115,545.

- Potential dilution: common shares issuable on convertible notes excluded from diluted EPS: 72,323,712 shares.

- Cash flow (six months): Net cash used in operating activities $(162,482); Cash provided by financing (related‑party advances) $162,763; Net increase in cash $281; Cash at period end $3,098.

- Discontinued subsidiary (Ga‑Du) dissolved April 3, 2025 - liabilities assumed $975,000; no revenues contributed.

- Accrued/unpaid executive compensation and related party exposure: CEO/CFO Michael Rountree accrued salary $1,565,000 (as of July 31, 2025) and expense reimbursements $333,174; Jeffery Taylor accrued $44,721; Don Lee Taylor accrued $426,450; Ombudsman advisory fees accrued to Mr. Mudd $550,000.

- Several notes are in default; convertible note holder has not demanded payment but the note is described as in default.

Positive aspects of the income statement

- R&D spending continues (three months R&D $80,053; six months $178,770) - shows ongoing product development on Herbo/HerboPay.

- Management & consulting fees remained relatively stable (three months $125,500; six months $251,000) - predictable operating cost line.

- Legal, accounting and audit fees reduced year‑to‑date (six months $37,790 in 2025 vs. $67,310 in 2024) - one cost category easing.

- Company kept operating cash burn roughly offset by related‑party financing during the six‑month period (operating cash outflow $(162,482) vs. related‑party inflows $162,763).

Negative aspects of the income statement

- Revenue: $0 - no commercial traction reported yet; zero top‑line is the dominant issue.

- Losses persist: six‑month net loss $(536,264); quarterly loss $(262,843) - recurring operating losses with interest burden.

- Interest and financing costs: six months interest expense $39,071 and multiple defaulted notes increase financial risk and creditor pressure.

- Heavy reliance on related‑party financing and accrued unpaid salaries - creates governance and sustainability questions and potential future dilution.

- Large potential dilution from convertible note conversion (72,323,712 shares) - significant overhang versus 52,957,572 shares outstanding.

- Going concern: the company explicitly states substantial doubt about continuing as a going concern without new funding.

Bottom line: ESSI is an early‑stage, development‑stage OTC‑quoted company with active software development but no revenue. Financials show low cash ($3,098), sizable liabilities ($17.2M), recurring operating losses and multiple related‑party funding arrangements and defaults. The immediate story is survival and capital-commercial execution (generating revenue) and fresh, non‑related‑party financing are the critical next steps.